Spectrum Pharmaceuticals snagged the rights to an orphan-designated, pivotal-stage cancer treatment coupled with a specialized delivery component that increases stability and solubility.
As plant problems drained away supplies of the important generic chemo drug leucovorin a few years ago, Spectrum Pharmaceuticals got to play the hero by upping production of its own branded version, Fusilev, or levoleucovorin.
The company plans to advance the program, which has fast-track status in the U.S., to an FDA review next year.
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant ( email | Twitter ) and Nesa Nourmohammadi (...
Spectrum Pharmaceuticals ($SPPI) put on the best face possible on the news that its bladder cancer drug apaziquone failed two late stage studies.
A recent example of the FDA stepping in to help alleviate a drug shortage involves high-flying Spectrum Pharmaceuticals and its anticancer drug, Fusilev (levoleucovorin, in 50-mg single-use vials).
This morning, MarketWatch's Michael Shulman listed some of what he sees are the hottest bargain biotech stocks for this year: Cerus, Curis, Compugen, Spectrum Pharmaceuticals and Impax Laboratories.
Spectrum Pharmaceuticals ( $SPPI ) is jumping into the biosimilar business. In a brief announcement this morning, the Irvine, CA-based biotech said that it has inked a deal with Viropro to develop a
Irvine, California-based Spectrum Pharmaceuticals is suing Cangene Biopharma in the U.S. District Court in Baltimore for allegedly breaching a 2008 contract to make Fusilev, an injectable cancer
Spectrum Pharmaceuticals is paying $30 million down and up to $320 million in cash and a million shares of stock for a significant share of the worldwide rights to a late-stage cancer compound